CYP3A4 and cancer: Our study aimed to examine whether the predominant pathway for oxycodone metabolism [6] – CYP2D6 and CYP3A4 – metaboliser status affect oxycodone dose, pain scores, and adverse effects in an Australian patient population with pain from advanced cancer, a population which commonly requires oxycodone [28].